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cert with several related NHLBI research programs, they
address the etiology, pathophysiology, and clinical pro-
gression of AAAs with an assortment of scientific
approaches and experimental strategies (Table). The
NHLBI held a meeting of Principal Investigators in
Bethesda, Md, on April 10 and 11, 2000, to establish con-
sensus on current research needs, identify additional
avenues for collaboration between individuals working in
diverse fields, and maximize the overall impact of the
aneurysm research program. The purpose of this report is
to summarize the information and perspectives discussed
at that meeting for the wider community of vascular sur-
geons, biologists, and basic scientists, according to four
broad areas of research: (1) proteolytic degradation of aor-
tic wall connective tissue, (2) inflammation and immune
responses, (3) biomechanical wall stress, and (4) molecu-
lar genetics.
PROTEOLYTIC DEGRADATION OF AORTIC
WALL CONNECTIVE TISSUE
Aneurysmal degeneration is the end result of a multi-
factorial process leading to the destruction of aortic wall
connective tissue.6 Compelling evidence indicates that the
most important structural elements in the aortic wall are
elastin and interstitial collagens and that AAAs are associ-
ated with increased local production of enzymes capable of
degrading these fibrillar extracellular matrix proteins.7
Much of this evidence is derived from studies on matrix
metalloproteinases (MMPs); four MMPs, including 72-
kD gelatinase (MMP-2), 92-kD gelatinase (MMP-9),
matrilysin (MMP-7), and macrophage elastase (MMP-12),
are capable of degrading elastic fibers, whereas at least three
other MMPs are specific for interstititial collagens.8-10
Other proteinases, such as plasminogen activators, serine
elastases, and cathepsins, may also contribute to aneurysmal
degeneration, and factors controlling connective tissue
repair are undoubtedly of considerable importance.
Mechanisms regulating connective tissue metabolism have,
Abdominal aortic aneurysms (AAAs) represent a com-
mon vascular condition with life-threatening implications.
Although basic research has led to a better understanding
of aneurysm disease in the past two decades, fundamental
knowledge about the process of aneurysmal degeneration
remains limited. The prevalence of AAAs is relatively high
in the general population, and current clinical options are
somewhat limited, making it apparent that an urgent need
for multidisciplinary approaches to investigate the cellular
and molecular nature of aneurysm disease and its compo-
nent mechanisms and transitional research to develop new
therapeutic strategies exist.1-5
In recognizing these concerns, the National Heart,
Lung, and Blood Institute (NHLBI) issued a Request for
Applications titled “Pathogenesis of Abdominal Aortic
Aneurysms” in December 1998 (RFA HL-99-007),
announcing a new program to support multidisciplinary
research programs on AAAs. After detailed peer review, 11
collaborative R01 research grants in seven different insti-
tutions were funded in September 1999. Each of these
programs is highly integrative and synergistic, and in con-
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therefore, attracted great interest within the NHLBI-sup-
ported programs on AAAs.
MMP-9 and aortic aneurysms—developing a
model. The long-term goal of the research group at
Northwestern University is to understand the role of
MMP-9 in the pathogenesis of AAAs. Preliminary studies
have demonstrated a significant correlation between
aneurysm size and aortic wall expression of MMP-9 mes-
senger RNA (mRNA), and patients with AAAs also exhibit
elevated plasma levels of MMP-9. On the basis of these
studies, the investigators proposed that the mechanisms of
arterial wall repair are abnormal in patients with AAAs,
with MMP-9 overexpression resulting in matrix destruc-
tion. The experiments being conducted are designed as a
means of testing this hypothesis by developing a novel in
vivo system to model the pathogenesis of aneurysms, in
which transgenic mice have been engineered to overex-
press MMP-9 under the direction of a vascular smooth
muscle cell (SMC)–specific promoter. These animals are
subsequently being used with a variety of experimental
“initiating events” as a means of characterizing the patho-
genesis of aneurysms, including mechanical and chemical
injury to the aorta, and as experimental models of “genetic
susceptibility,” including hypertension and atherosclerosis
(ie, apolipoprotein knockout mice). The investigators are
also expanding their evaluation of plasma MMP-9 levels in
patients with aneurysms, as compared with age- and sex-
matched control subjects with aortic occlusive disease.
They will establish the optimal sensitivity and specificity
for plasma MMP-9 levels by using receiver-operating-
characteristic and multiple logistic regression analyses, and
plasma MMP-9 levels will be followed longitudinally in a
subgroup of patients not undergoing AAA repair to help
predict rapid expansion. Plasma MMP-9 levels will also be
followed in patients undergoing open and endovascular
repair as a means of determining the prognostic usefulness
of these analyses.11-13
MMP regulation by doxycycline in aortic aneu-
rysms. Complementary work is being done at the
University of Nebraska, where investigators point out that
although MMP-9 may have a role in AAAs, there is also a
significant increase in total MMP-2 in human AAA tissue.
They found that a larger proportion of the MMP-2 in
AAA tissue is in the active form, compared with the
proenzyme, and that much of this enzyme is bound to the
extracellular matrix, which suggests a direct and ongoing
role in proteolysis. They have also demonstrated that
AAA tissue contains increased levels of membrane type-1
MMP (MMP-14), the principal activator of proMMP-2,
and that doxycycline inhibits MMP-2 production by aor-
tic SMCs in culture. The investigators therefore proposed
that MMP-2, through its increased activation, has a cen-
tral role in aneurysm formation and that this can be inhib-
ited by doxycycline. They will examine this hypothesis
through these specific aims: (1) determine the effects of
individual MMPs implicated in AAAs, including MMP-2,
MT1-MMP, MMP-9, and MMP-12, on the size and rate
of aneurysm formation in a murine AAA model; (2)
determine the effects of doxycycline on the size and rate
of murine aneurysm formation and AAA progression and
correlate these effects with serum doxycycline levels; and
(3) determine the mechanisms by which doxycycline
downregulates MMPs in human aortic SMCs. The first of
these aims will be accomplished with the use of a novel
mouse model of AAAs with various knockout mice,
including animals deficient in MMP-2, MMP-9, or
MMP-12. They will also use a tissue inhibitor of metallo-
proteinases-2 knockout mouse, in which proMMP-2 can-
not be activated. The second aim will examine how
doxycycline influences the murine model of AAAs by cor-
relating its effects on aortic wall MMP expression,
aneurysm size, and growth with serum doxycycline con-
centrations. The third aim will be accomplished by deter-
mining MMP-2 mRNA levels, half-lives, and rates of
transcription in vascular SMCs and by identifying the
doxycycline-response elements that may exist in the
MMP-2 promoter. The long-term goal of this work is to
develop novel pharmacologic therapies to specifically tar-
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get the MMPs important in aneurysm pathogenesis and
progression.14,15
Molecular mechanisms of aneurysmal degenera-
tion. Investigators at Washington University in St Louis
have designed an additional program to understand the
regulation of individual gene products within the aneurys-
mal aorta and their pathophysiologic implications in dis-
ease progression. They have characterized small animal
models of elastase-induced aortic injury that recapitulate
many of the critical features of human AAAs, including
transmural infiltration of the aortic wall by mononuclear
phagocytes, increased local production of MMPs, and
progressive degradation of aortic wall matrix proteins.
They have also demonstrated the feasibility of pharmaco-
logically suppressing aneurysmal degeneration in vivo, by
using anti-inflammatory agents and nonselective MMP
inhibitors (eg, doxycycline). More recent investigations
have resulted in two important observations. First, elas-
tase-induced aneurysmal degeneration in mice is sup-
pressed by targeted gene disruption of MMP-9, but is
unaffected in animals deficient in MMP-12; furthermore,
bone marrow transplantation from wild-type mice pre-
vents the aneurysm-resistant phenotype in MMP-9–
deficient animals, and wild-type mice acquire aneurysm
resistance after transplantation from MMP-9–deficient
donors. Second, systemic administration of doxycycline
was found to reduce aortic wall expression of MMP-9
mRNA as much as fivefold in patients undergoing elective
AAA repair, and physiologically relevant concentrations of
doxycycline suppressed phorbol-stimulated expression of
MMP-9 in cultured human THP-1 mononuclear phago-
cytes. To build on these observations, the investigators are
pursuing four specific aims to identify the critical molecu-
lar steps involved in elastase-induced aneurysmal degener-
ation in the mouse and elucidating the molecular pathways
by which aneurysmal degeneration might be suppressed
by MMP-inhibiting tetracyclines: (1) determine whether
the generation of biologically active elastin degradation
peptides is responsible for leukocyte recruitment, aortic
wall infiltration, and MMP expression during the initiation
of elastase-induced AAAs; (2) clarify the molecular mech-
anisms by which targeted deletion of MMP-9 suppresses
the development of elastase-induced AAAs; (3) establish
whether urokinase-type plasminogen activator (u-PA),
plasmin, or additional MMPs are required during the
development of elastase-induced AAAs; and (4) define the
molecular mechanisms by which doxycycline suppresses
phorbol-stimulated expression of MMP-9 in cultured
human mononuclear phagocytes.16-18
Regulated expression of collagenases in AAAs. A
second program at Washington University is focused on
the possibility that collagen-specific enzymes are responsi-
ble for the clinical progression of AAAs. The investigators
point out that the progression of aneurysm disease cannot
be explained solely on the basis of elastin degradation and
that considerable evidence implicates the breakdown of
interstitial (types I and III) collagens in diminishing the
tensile strength of the aneurysmal aorta. They also note
that increased collagen synthesis may counteract collagen
degradation in stable, intermediate stages of aneurysm dis-
ease, but that, at later stages, a negative balance favoring
collagen degradation may precipitate rapid aneurysm
expansion and rupture. The investigators reemphasized
that the dissolution of interstitial collagens requires the
action of collagenases that can cleave intact collagen fibers
within their cross-linked triple helix domains and that
three MMPs can efficiently catalyze this reaction. In pre-
liminary studies, the investigators demonstrated that the
expression of collagenase-1 (MMP-1) is highly variable in
human aneurysm tissues, but that collagenase-3 (MMP-
13) is more consistently expressed in human AAA tissue
and by vascular SMCs in culture. Moreover, they found
that SMC expression of MMP-13 is regulated in a manner
that is profoundly distinct from MMP-1, consistent with
MMP-13 exhibiting a relatively limited tissue distribution
and often being regulated differently from other MMPs.
These observations have raised the possibility that MMP-
13 might have a substantial role in the pathophysiology of
aortic aneurysms. The goals of this proposal are to: (1)
determine the relative expression and tissue distribution of
the three collagenases in human AAA tissue and define
how the expression of each enzyme is influenced by the
clinical stage of disease; (2) identify extracellular ligands
and signaling mechanisms that differentially regulate the
expression of MMP-1 and MMP-13 in cultured vascular
SMCs; and (3) elucidate the transcriptional mechanisms
by which MMP-13 is regulated in vascular SMCs, as com-
pared with other cell types.19-21
Oxidative mechanisms of AAA formation. In a
third program at Washington University, investigators rea-
son that the elastin and collagen degradation in AAAs is
likely triggered by the activation of latent MMPs. The
investigators noted that MMPs possess a common struc-
tural motif, the “cysteine switch,” in which the latent state
is preserved by interactions between a cysteine residue in
the propeptide domain and the zinc atom in the active
site; thus, a variety of thiol-reactive reagents and
chaotropic agents are potent activators of MMPs in vitro.
The investigators proposed that reactive oxygen interme-
diates (ROIs) might expose the active site through reac-
tion with thiol groups on the propeptide, thereby
damaging the cysteine switch, and that inflammatory cells
in AAA tissue might mediate such reactions. Earlier stud-
ies indicate that activated phagocytes produce O2–– with a
membrane-associated reduced nicotinamide adenine dinu-
cleotide phosphate oxidase and that this dismutates to
hydrogen peroxide (H2O2), which can serve as an oxidiz-
ing substrate for myeloperoxidase (MPO), another phago-
cyte product. MPO greatly amplifies the toxic potential of
H2O2, generating potent oxidants in large part by reaction
with chloride [H2O2 + Cl– + H+ ↔ HOCl + H2O]. It has
been demonstrated that HOCl generated by MPO can
activate latent MMP-8 and MMP-9; although MMP-8
and MMP-9 are structurally distinct and exhibit very dif-
ferent substrate specificities, their behavior with HOCl
suggests a common activation mechanism. The investiga-
tors plan to test the hypothesis that ROIs activate
proMMPs by covalently modifying the sulfur group of the
cysteine switch. They will first examine the effect of ROIs
on a model peptide that mimics the cysteine switch. This
cysteine switch peptide will be incubated with various
ROIs in conditions associated with MMP activation in
vitro, and the reaction mixture will be subjected to high-
performance liquid chromatography and mass spectromet-
ric analysis. If the peptide has been covalently modified, its
apparent molecular mass will increase. The investigators
will then use tandem mass spectrometry as a means of con-
firming the specific nature of the modification and identi-
fying the precise site at which it occurs. They will then
determine whether similar changes occur when ROIs acti-
vate intact proMMPs in vitro. Collectively, the proposed
studies should determine whether oxidants convert
proMMPs into active MMPs by covalently modifying the
thiol group of the cysteine switch. This will provide
important insight into the mechanisms of MMP activation
and lay the groundwork for determining whether similar
events trigger MMP activation in human AAAs.22-24
Posttranscriptional regulation of tropoelastin
expression. Other investigators at Washington University
have focused on elastogenesis as a potential mechanism of
connective tissue repair in AAAs. They point out that
elastin is composed of cross-linked tropoelastin monomers
and that the production of elastin is unique among con-
nective tissue proteins in that tropoelastin expression is lim-
ited to a brief period of development; thus, elastic fiber
assembly is complete by maturity, and tropoelastin synthe-
sis ceases. The molecular control of elastogenesis needs to
be delineated to understand the mechanism of aberrant
production, but insufficient information exists on the nor-
mal regulation of tropoelastin expression. On the basis of
preliminary data indicating that the downregulation of
tropoelastin expression is uniquely controlled at a post-
transcriptional level, the investigators proposed to under-
take a detailed molecular characterization of this
mechanism. They will test the hypotheses that the cessation
of elastogenesis is normally controlled by accelerated decay
of tropoelastin mRNA and that this regulatory mechanism
involves specific sequences in the transcript. The generality
of this mechanism will be determined by assessing the reg-
ulation of tropoelastin production in different conditions,
such as hormone treatment, time in culture, and age of the
cell donor, and with models of in vivo elastin production
during development. The effect on tropoelastin transcrip-
tion, which is expected to be minimal, will be assessed by
means of nuclear runoff assays, reverse transcription/poly-
merase chain amplification of tropoelastin pre-mRNA, and
transfection with tropoelastin promoter-plasmid con-
structs. Because transcript turnover can be affected by
diverse pathways, a detailed characterization of the acceler-
ated degradation of tropoelastin mRNA will be performed
with different methods. Specific enzymatic decay of
tropoelastin mRNA will be examined as a means of deter-
mining whether such mechanisms are activated in response
to inhibitors of elastin production. A nuclease protection
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assay will be used as a means of determining whether the
status of polyadenylation correlates with the turnover of
tropoelastin mRNA, and regulatory sequences in the
mRNA will be identified by monitoring the response of
reporter constructs containing defined sequences coding
for tropoelastin mRNA. The interaction of these and other
sequences with cellular factors will be determined by means
of gel retardation assays with synthetic fragments of
tropoelastin mRNA. Information from these studies will
provide new and valuable information on the control of
elastogenesis and will eventually lead to characterization of
specific cellular factors regulating elastin production in
development and disease.25-29
Cysteine proteases in AAAs. In addition to pro-
grams concentrating on MMPs, investigators from
Harvard University/Brigham and Women’s Hospital have
called attention to the possibility that certain cysteine-
dependent elastolytic enzymes might also play a role in
aneurysm disease. Cathepsins are broadly distributed
members of the papain superfamily with pH optima in the
acidic range. Because they act intracellularly within acidic
lysosomes, cathepsins have not been accorded a substantial
role in extracellular matrix degradation and have therefore
been overlooked in earlier studies on AAAs. The investi-
gators emphasized that cathepsin S differs from other cys-
teine proteases because of its restricted tissue distribution,
high elastolytic activity at neutral pH, and its capacity to
degrade proteins outside the intracellular domain.
Preliminary studies have demonstrated that cathepsins S
and K are potent elastases and that the genes encoding
these enzymes are expressed in human atheroma. Tissue
extracts from atheroma also have elevated elastolytic activ-
ity sensitive to cysteine protease inhibitors, and vascular
SMCs have been established as a novel source of cathep-
sins S and K in vivo and in vitro. The investigators have
also shown that cultured human SMCs respond to inter-
feron-γ stimulation by secreting an active cysteine protease
that can degrade insoluble elastin, and increased cathepsin
S expression has been documented in atherosclerotic
plaques and aortic aneurysms with immunohistochemistry
and Western blot analysis. The investigators also point out
that cystatin C is the most abundant endogenous cathep-
sin inhibitor and that a reciprocal decrease of cystatin C
occurs in atherosclerotic plaques and AAAs compared with
normal aorta. Moreover, serum levels of cystatin C are
markedly decreased in patients with subclinical aortic
dilatation. Cathepsin S, therefore, shows a shift of
enzyme/inhibitor balance in atherosclerosis and AAAs,
indicating the need for further study of aneurysm forma-
tion, progression, and rupture. Further studies in low-
density lipoprotein receptor-deficient mice that lack either
cathepsin S or cystatin C will test the role of cathepsins in
experimental atherogenesis and aneurysm formation.30,31
INFLAMMATION AND IMMUNE REPSONSES
Chronic inflammation is a prominent feature of AAAs,
and inflammatory cells likely mediate much of the connec-
tive tissue destruction in the aortic wall.10 The factors stim-
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ulating inflammatory cell recruitment and activation in the
outer aortic wall are therefore critical in understanding the
pathogenesis of aneurysm disease.32 In addition, there are
compelling reasons to believe that the immune response
contributes to aneurysmal degeneration, raising the possi-
bility that autoimmunity may even be responsible for the
pathogenesis and progression of aneurysmal disease.33,34
This possibility is supported by the presence of inflamma-
tory infiltrates in AAAs comprised of T-cells, mono-
cyte/macrophages, B lymphocytes, and plasma cells; the
presence of human lymphocyte antigen (HLA)-DR+ T-cells
and monocytes in AAA tissue; an association between par-
ticular HLA alleles and susceptibility to AAAs; and the
demonstration that immunoglobulin G purified from AAA
specimens is immunoreactive with proteins isolated from
normal aortas. Understanding the nature of the immune
response in AAAs is therefore an important component of
the NHLBI research program.
Is AAA an antigen-driven autoimmune disease?
Investigators at Temple University School of Medicine are
addressing the possibility that AAAs may be initiated by an
antigen-driven T-cell response directed against self or non-
self antigens. Several cell types present in AAAs may func-
tion as antigen-presenting cells to T-lymphocytes, including
macrophages, activated endothelium, and SMC expressing
HLA-DR. Although it is not yet known whether the
inflammatory response is antigen driven, a number of puta-
tive antigens, including elastin, interstitial collagens, oxi-
dized low-density lipoprotein, aortic aneurysm antigenic
protein-40, and cytomegalovirus, have been suggested.
Despite the prevalence of T-cells in AAAs, there is very lit-
tle known about their role in the initiation and propagation
of the disease, and it is possible that specific antigen recog-
nition by T-cells might trigger a cascade of events leading to
extracellular matrix destruction within the aorta. It is also
possible that T-cells infiltrating AAA lesions become acti-
vated by a process known as “molecular mimicry,” in which
common epitopes shared between microorganisms and host
proteins cause a form of immunological cross-reactivity.
Because molecular mimicry may result in autoimmune dis-
ease, this mechanism may play a role in the pathogenesis of
AAAs. The hypothesis to be tested in these studies is
whether an antigen-driven T-cell response may be responsi-
ble for the initiation and propagation of AAAs and whether
the T-cells present in AAAs recognize host antigens. The
investigators will first determine whether mononuclear cells
within AAA tissue contain oligoclonal populations of T-cells
by studying the T-cell receptor (TCR) sequences of the
infiltrating T-cells; although TCRs are highly polymorphic,
each individual clone of T-cells expresses a unique TCR,
which can serve as a “fingerprint” of T-cell (clonal) popula-
tions. In the second part of the study, the investigators will
examine whether these T-cells recognize certain putative
antigens in AAA tissue.35
Autoimmune aortic antigens in AAAs. Investi-
gators from Columbia University/St Luke’s-Roosevelt
Hospital have partially characterized several proteins 
that may serve as autoantigens in some patients with
AAAs. The first of these to be identified was named
aneurysm-associated antigenic protein-40 kD (AAAP-
40). AAAP-40 resembles the 36-kD microfibril-associ-
ated glycoprotein (MAGP-36), which has been described
as an aorta-specific protein in cows and pigs. With an anti-
body raised against a unique AAAP-40 oligopeptide, it
was revealed by means of immunohistochemistry that the
immunoreactive protein is most abundant in adventitial
microfibrils associated with collagen in the aorta and iliac
arteries. Although it was also detected in other vessels,
including the carotid and popliteal arteries, AAAP-40
appears to be an artery-specific antigenic protein (ASAP)
because it was not detected in tissues outside the arterial
tree. Other features of AAAP-40 include similarity to all
three fibrinogen chains (suggesting a common evolution-
ary ancestor with the fibrinogen precursor) and a short
sequence similarity to vitronectin. By screening a human
aortic wall complementary DNA library with antibodies
to human vitronectin, the investigators have now isolated
additional sequences named recombinant clones (r-Cl)-1,
-4, and -5. All have fibrinogen-like motifs, and their mol-
ecular weights are in the 28 to 30 kD range. Antibodies
raised against unique sequences of r-Cl-1 and r-Cl-5 sug-
gest that they are additional members of a “superfamily”
of collagen-associated microfibrillar proteins. Protein
immunoreactive with antibody against r-Cl-5 was not 
limited to the aortoiliac segment, but was also detected
on peritoneal surfaces and in other extra-arterial loca-
tions. Because variation in the immune response against
one or more of these proteins may be the basis for the
observed phenotypic variability of aneurysmal diseases,
the investigators plan to apply further molecular ap-
proaches with human and animal tissues to isolate, purify,
and sequence ASAP family proteins and to search for
common sequences and antigenic epitopes that might
elicit immune reactions in the aorta. They will then relate
them to other identified proteins likely to share these
immunogenic properties.36-41
BIOMECHANICAL WALL STRESS
Hemodynamic stress on the aortic wall is of obvious
importance in aneurysm rupture, but may also play a role
in aneurysm development. In this respect, the infrarenal
abdominal aorta is particularly prone to atherosclerotic
plaque formation and aneurysmal enlargement, whereas
the thoracic aorta is relatively resistant. The reasons for
these regional differences in susceptibility are unknown,
but may involve a combination of differences in structure,
composition, nutrition, and biology of the aortic wall and
differences in the hemodynamic flow field and biome-
chanical forces applied to the aortic wall in time.42
Projects focusing on the analysis of biomechanical wall
stress are therefore a valuable component of the NHLBI
research program on AAAs.
Quantitation of biomechanical determinants of
human AAAs. Investigators at Stanford University
described their initial efforts to test the hypothesis that
hemodynamic forces and cumulative biomechanical stress
and strain result in aortic wall tissue failure and aneurys-
mal dilation. They presented their methods to quantify
blood flow and vessel strain with magnetic resonance
imaging and computational modeling techniques. It has
been demonstrated by means of preliminary results with
magnetic resonance imaging that cyclic wall strain can be
measured accurately in vitro and that in vivo methods are
viable. The investigators have created computational solu-
tions for three-dimensional (3-D) pulsatile blood flow in a
model of the entire aorta and in AAAs and are now relat-
ing the differences in the pulsatile flow field to differences
in aortic structure, composition, and mechanical properties
between the thoracic and abdominal aorta. Computational
methods to quantify blood flow and vessel wall mechanical
behavior of normal human thoracoabdominal aortas and
aneurysmal abdominal aortas are also in progress. The
long-term goal of the investigators is to develop a quanti-
tative computer-based information framework to integrate
biological and biomechanical theories for testing hypothe-
ses about human aneurysm pathogenesis.43,44
Mechanobiologic determinants of experimental
AAAs. A second group at Stanford University has pro-
posed experiments to define the molecular mechanisms by
which hemodynamic and inflammatory influences facili-
tate AAA development, to quantitatively define the vary-
ing hemodynamic forces that act on the human aorta
resulting in mechanical failure of the aortic wall and
aneurysmal enlargement, and to characterize pathologic
alterations in the humoral and biomechanical milieu lead-
ing to maladaptive remodeling of the vessel wall. By using
animal models, the investigators hypothesize that the ini-
tiation and progression of compensatory arterial enlarge-
ment (and, consequently, aneurysmal dilatation) is
regulated by the patterns of genetic expression by resident
and infiltrating cells within the aortic wall. They will
undertake experiments to define the patterns of gene
expression associated with flow-mediated aortic enlarge-
ment, modified wall motion, and inflammatory aortic
enlargement. They have also designed experiments to test
the hypothesis that biomechanical factors may mediate the
initiation and progression of aneurysmal degradation via
transduction of specific humoral factors that influence
inflammation in the degenerating aorta. To achieve these
aims, the investigators will use four rat models: (1) aortic
elastase infusion; (2) proximal aortic coarctations; (3) dis-
tal aortic coarctations; and (4) femoral arteriovenous fis-
tulae (AVF). Patterns of aortic gene expression in each
model will be analyzed on a custom gene chip containing
representative oligonucleotide probes from all published
rat genes, and confirmatory analysis of mRNA and protein
synthesis will be performed. Immunohistochemistry and
in situ hybridization will help to further define the role of
resident versus infiltrating cells in aneurysm pathogenesis,
and physical forces, such as wall motion (wall strain) and
flow (shear stress), will also be analyzed. Combinations of
AVF and coarctations will then be used to alter aortic wall
strain and shear stress to determine how these hemody-
namic changes alter the pattern of inflammatory gene
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expression. Information gained on mechanobiologic fac-
tors mediating experimental aortic aneurysms will prove
useful in designing novel strategies to prevent AAA expan-
sion and enlargement in humans.45,46
Role of wall stress distribution in AAAs. Investi-
gators at Dartmouth-Hitchcock Medical Center will use
computed tomography (CT) imaging, computer-gener-
ated 3-D reconstructions of CT data, and mathematical
techniques to calculate aortic wall stress with new and
sophisticated computer models. They point out that physi-
cians have long sought the ability to identify patients with
a high risk of AAA rupture and to distinguish them from
those at relatively low risk. The basic premise of the pro-
posed project is that aneurysm rupture occurs when the
mechanical wall stress (ie, internal forces per unit area)
exceeds the maximum stress that the aneurysmal tissue can
inherently withstand (ie, failure strength); thus, when the
wall stresses on a particular AAA are known, then one may
make reliable predictions about its rupture risk. In addi-
tion to the recognized contributions of AAA diameter and
blood pressure, aneurysm wall stress is greatly dependent
on aneurysm shape, but this factor is seldom considered in
the clinical setting because the technology needed to pre-
cisely determine AAA shape did not exist until recently.
The proposed project will consist of three major elements.
The first will test the basic hypothesis that wall stress is
directly related to AAA rupture. Stress analysis will be per-
formed on 20 AAAs near the time of rupture in which CT
data were coincidentally obtained within the previous
month and on 50 size-matched AAAs that did not rupture
in a longer time span. The 3-D wall stress distribution
(including peak, mean, and cyclic wall stresses) will be
compared between the two groups. The second element of
the study will involve the analysis of wall stress distribution
in at least 30 AAAs that have been followed in extended
periods of time; changes in wall stress distribution will be
evaluated as a means of examining their role in AAA expan-
sion and progression, including analysis of 3-D shape and
how it changes with time. The third element of the project
will involve refinement of the noninvasive methodology
used as a means of determining AAA wall stress distribu-
tion by reanalyzing CT data from the other two elements
of the study, with proposed refinements in computer mod-
eling. These studies will provide critical insight into the
role of wall stresses during AAA disease progression and
rupture and may provide noninvasive tools for more accu-
rately predicting patient outcomes.47,48
Saccular intracranial aneurysms—size, shape, and
behavior govern rupture. Investigators from Texas A &
M University discussed the similarities and differences
between AAAs and intracranial aneurysms, pointing out
that intracranial aneurysms are focal dilatations of the arte-
rial wall that arise in and near the circle of Willis. These
aneurysms generally occur in one of two forms: fusiform
lesions, which occur primarily along the basilar artery, and
saccular lesions, which usually develop at the apex of a
bifurcation. Fusiform aneurysms are often referred to as
space occupying because they produce symptoms by press-
ing on adjacent tissue; they tend to be atherosclerotic and
affect the vessel around its entire circumference. Saccular
aneurysms occur predominantly in the anterior and mid-
dle portions of the cerebral vasculature in as much as 5%
of the general population; they are often asymptomatic
until rupture and represent the leading cause of sponta-
neous subarachnoid hemorrhage. They can have either 
a narrow or a broad neck, but are only complicated by 
atherosclerosis after they have enlarged significantly.
Although saccular intracranial aneurysms and AAAs have
different etiologies, many aspects of their natural history
and treatment are similar. It has been hypothesized that
saccular aneurysms enlarge and rupture from material
instabilities, because of either a limit point instability, sim-
ilar to the rapid expansion of an inflated rubber balloon,
or resonance, which occurs when a structure is excited at
its natural frequency. Recent studies have challenged this
hypothesis, showing that processes of growth and connec-
tive tissue remodeling may constitute the primary deter-
minants of their natural history. Thus, it is now thought
that mechanical stresses (both shear stress caused by
altered hemodynamics and wall tension caused by blood
pressure acting on the thin curved aneurysm wall) serve to
signal collagen remodeling mediated by endothelial cells
and fibroblasts, so as to return the biomechanical tissue
environment toward homeostasis. In the case of well-bal-
anced tissue remodeling, the lesion may stabilize once it
achieves a new (optimal) configuration; in the case of an
imbalance, the lesion may suffer catastrophic weakening
that results in rupture. True interdisciplinary approaches
to understanding the mechanisms underlying aneurysm
disease will therefore have an important impact on these
conditions, regardless of anatomic location.49-52
MOLECULAR GENETICS
Familial aggregation of AAAs is widely recognized,
and a major gene effect has been suggested by means of
segregation studies. Other findings support the familial
nature of AAAs: (1) patients with a history of familial
AAAs (FAAAs) are significantly younger than those with
sporadic AAAs (SAAAs) at the time of diagnosis or rup-
ture; (2) rates of rupture are higher in patients with
FAAAs than in those with SAAAs; (3) the relative risk for
family members of patients with FAAAs is 18-fold higher
than for family members of patients with SAAAs; (4) rup-
ture rates are higher in women with AAAs than in men;
(5) the man-to-woman ratio in patients with SAAAs is 6:1,
whereas it is only 2:1 in patients with FAAAs; and (6) sub-
stantial ethnic variations exist in the prevalence of AAAs.
Although alternative explanations may be proposed for the
differences in outcomes between male and female patients,
it is quite possible that these differences are caused by spe-
cific genetic factors. Indeed, it might be expected that
when aneurysm disease does occur in women, it is caused
by the presence of a larger number of inherited liabilities,
a phenomenon characteristic of multifactorial diseases.
Women with AAAs would then represent the more severe
spectrum of the aneurysmal disease, and their first-degree
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relatives would be expected to be at a higher risk of devel-
oping AAAs.
By using affected sibling pair (ASP) DNA linkage
analysis, investigators from Wayne State University in
Detroit are working in collaboration with scientists at
Queen Elizabeth II Health Science Center (Halifax,
Canada), the University of Liege (Belgium), and Case
Western Reserve University (Cleveland, Ohio) to identify
the chromosomal regions likely to harbor the AAA sus-
ceptibility gene(s). As of April 2000, DNA samples have
been collected from 65 ASPs for this study. The investiga-
tors will identify additional affected-relative-pairs with
AAAs and collect DNA to identify alleles shared as identi-
cal by descent. First-degree family members aged at least
55 years will be offered abdominal ultrasound scanning as
a means of detecting asymptomatic AAAs. The linkage
analyses will be performed as model-free affected sib-pair
and pedigree analyses with a two-stage design. The first
stage of phase I will consist of a genome scan on the 65
ASPs collected to date, with highly polymorphic markers
located on average 10 cm apart (about 390 markers to
scan all human chromosomes). The second stage will
include genotyping additional markers from regions that
warrant further investigation on the basis of the initial
results. In phase II, the investigators will use additional
ASPs to type markers in chromosomal regions determined
to be sufficiently interesting in phase I, then perform
model-free linkage analyses in those regions by using the
combined data set. As a supplement to the genome scan,
genetic association studies will be carried out for selected
candidate loci by using DNA samples collected from unre-
lated patients with AAAs and control subjects; the initial
candidate loci to be investigated include MMPs and HLA
class II antigens. The long-term goal of this project is to
identify the gene or genes that harbor mutations in
patients with AAAs, yielding important information about
the genetic factors contributing to the development of
AAAs and potentially providing the basis for genetic test-
ing to identify individuals at risk. The proposed work will
also identify candidate genes and pathways of potential
importance in the pathogenesis of AAAs, opening new
avenues of research to investigate their function in trans-
genic animals and by pharmacologic intervention. The
work will also advance related fields of research, such as
statistical genetics, by providing real data sets to test new
approaches for the analysis of complex diseases.53-55
CONCLUSIONS
It is evident that current needs for basic research on
AAAs encompass a broad spectrum of potential areas for
investigation. Conceptual models of aortic aneurysm dis-
ease have traditionally focused on its mechanical aspects,
and consequently, surgical solutions have dominated the
therapeutic approach to this problem. However, with
increasing recognition of the prevalence of small AAAs
and the unfavorable natural history of these lesions, it is
apparent that a broader base of interdisciplinary attention
is needed. It is expected that rapid progress on the prob-
lem will be stimulated by attracting investigators with
expertise in a variety of disciplines to studies focused on
AAAs, to apply and integrate approaches involving vascu-
lar physiology, tissue-specific pathology, vascular cell biol-
ogy, molecular analysis of gene expression, clinical
investigations, and molecular genetics. More careful char-
acterization and creative use of human tissue resources will
expedite this effort, as will the development of more rep-
resentative animal models of AAAs. A more detailed analy-
sis of factors influencing the evolution of aneurysm disease
in different clinical settings, particularly those exploring
new avenues for clinical management of small AAAs, is also
likely to generate new testable hypotheses. These efforts
will necessarily include physicians specializing in vascular
surgery, cardiology, and vascular medicine, as well as basic
scientists focusing on various aspects of connective tissue
biology, inflammation and immunology, biomechanics,
and molecular genetics. Further efforts to foster strong
collaborations between basic and clinical investigators are
therefore needed to better understand the etiology, patho-
physiology, and natural history of aortic aneurysms.
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